A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Conditions

• Idiopathic Hypersomnia
• Narcolepsy Type 1
• Narcolepsy Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• ORX750 — DRUG
  ORX750 capsule.
• Placebo — DRUG
  ORX750 matching placebo capsule.

Study Details

Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities. While all conditions result in feeling sleepy, there are some differences in other common symptoms: * NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night. * NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy. * IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up. Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton (also known as ORX750) is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can help people with NT1, NT2, and IH feel less sleepy and make other symptoms better.

Key Dates

Start date

Dec 23, 2024

Status verified

Apr 2026

Primary completion

Dec 31, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

248 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Narcolepsy Type 1: ORX750 and Placebo
• Experimental: Narcolepsy Type 2: ORX750 and Placebo
• Experimental: Idiopathic Hypersomnia: ORX750 and Placebo

Primary Outcome Measure

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs [ Time Frame: Up to Day 35 ]

Central Contacts

• Centessa Pharmaceuticals
  +1 617-468-5770
  [email protected]

Locations (29)

Find similar trials in Auburn, AL

Related Studies

• Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
  Enrolling By Invitation · Mayo Clinic · Scottsdale, Arizona
• A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
  PHASE2/PHASE3 · Recruiting · Takeda · Birmingham, Alabama
• Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
  PHASE4 · Recruiting · Mayo Clinic · Phoenix, Arizona
• Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
  PHASE1 · Not Yet Recruiting · Nyree Penn · Aventura, Florida